Analyst
Equibles does not estimate personal net worth.
Akos has spoken on 5 investor events across 1 company, most recently for Aktis Oncology, Inc. on May 27, 2026. The companies whose calls Akos spoke on are classified in the Healthcare sector.
“AKY2519 is our novel, potentially first-in-class miniprotein radioconjugate targeting B7H3-expressing Like other miniproteins from our proprietary radioconjugate platform, it combines high affinity with highly selective binding to its target, in this case B7H3, with pharmacological properties that allow for deep tumor…”
“So it's dose escalation under the Boyne principle where we tend to do three to four patients per dose level as we move up through escalating doses.”
“So it's dose escalation under the Boyne principle where we tend to do three to four patients per dose level as we move up through escalating doses.”
“So as Matt just explained, our clinical development strategy for AKY2519 aligns closely with our vision to bring radiothermaceuticals to large tumor types, where we continue to see high unmet need.”
“So as Matt just explained, our clinical development strategy for AKY2519 aligns closely with our vision to bring radiothermaceuticals to large tumor types, where we continue to see high unmet need.”
AKTS
Biotechnology · Healthcare
